Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 0.1086 | 0.5901 | 1 |
Echinococcus granulosus | Aminotransferase class III | 0.0154 | 0.0671 | 1 |
Toxoplasma gondii | ornithine aminotransferase, mitochondrial precursor, putative | 0.0154 | 0.0671 | 0.5 |
Echinococcus multilocularis | Aminotransferase class III | 0.0154 | 0.0671 | 1 |
Onchocerca volvulus | 0.1816 | 1 | 1 | |
Loa Loa (eye worm) | pax transcription factor protein 2 | 0.1816 | 1 | 1 |
Echinococcus multilocularis | ornithine aminotransferase | 0.0154 | 0.0671 | 1 |
Schistosoma mansoni | ornithine--oxo-acid transaminase | 0.0154 | 0.0671 | 1 |
Mycobacterium ulcerans | adenosylmethionine-8-amino-7-oxononanoate aminotransferase | 0.1086 | 0.5901 | 1 |
Mycobacterium leprae | PROBABLE ADENOSYLMETHIONINE-8-AMINO-7-OXONONANOATE AMINOTRANSFERASE BIOA | 0.1086 | 0.5901 | 1 |
Echinococcus multilocularis | ornithine aminotransferase | 0.0154 | 0.0671 | 1 |
Plasmodium falciparum | ornithine aminotransferase | 0.0154 | 0.0671 | 0.5 |
Mycobacterium tuberculosis | Probable aminotransferase | 0.1086 | 0.5901 | 1 |
Wolbachia endosymbiont of Brugia malayi | acetylornithine transaminase protein | 0.0154 | 0.0671 | 0.5 |
Brugia malayi | 4-aminobutyrate aminotransferase, mitochondrial precursor | 0.0154 | 0.0671 | 0.0671 |
Plasmodium vivax | ornithine aminotransferase, putative | 0.0154 | 0.0671 | 0.5 |
Trichomonas vaginalis | acetylornithine aminotransferase, putative | 0.1086 | 0.5901 | 0.5 |
Echinococcus granulosus | ornithine aminotransferase | 0.0154 | 0.0671 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.1086 | 0.5901 | 1 |
Chlamydia trachomatis | glutamate-1-semialdehyde-2,1-aminomutase | 0.0154 | 0.0671 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ACT (functional) | = -6 | Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg. | ChEMBL. | 1956040 |
AERP (functional) | = 52 | Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg. | ChEMBL. | 1956040 |
APD (functional) | = 22 -60mV | Repolarization of the compound to reach -60mV, in canine Purkinje Fibers at a concentration of 3.0 uM at 300 ms (simulating tachycardia) | ChEMBL. | 1956040 |
APD (functional) | = 45 -60mV | repolarization of the compound to reach -60mV, in canine Purkinje Fibers at a concentration of 3.0 uM at 1000 ms (simulating normal heart rate) | ChEMBL. | 1956040 |
HR (functional) | = -23 | Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg. | ChEMBL. | 1956040 |
MBP (functional) | = -11 | Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg. | ChEMBL. | 1956040 |
VCT (functional) | = 1 | Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg. | ChEMBL. | 1956040 |
VERP (functional) | = 30 | Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg. | ChEMBL. | 1956040 |
Vmax (functional) | = 3 | Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 3.0 uM at 300 ms (simulating tachycardia) | ChEMBL. | 1956040 |
Vmax (functional) | = 5 | Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 3.0 uM at 1000 ms (simulating normal heart rate) | ChEMBL. | 1956040 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.